By Dean Seal
Teva Pharmaceuticals and Sanofi report that the latest trial of their jointly developed treatment for inflammatory bowel disease met its primary endpoints.
The companies said Tuesday that patients with ulcerative colitis who were treated with duvakitug achieved a higher rate of clinical remission compared with a placebo group. A group of patients with Crohn's disease who were treated with duvakitug achieved a higher rate of remission than those treated with a placebo.
The treatment effect was consistent across subgroups, the companies said.
Teva's shares surged 18% to $19.53 in premarket trading. Sanofi's American depositary receipts were up 3.7% at $47.57.
Duvakitug was generally well tolerated across both patient groups and showed similar rates of treatment-emergent adverse events.
Teva Chief Medical Officer Eric Hughes said the results exceeded expectations.
"I am deeply moved by the potential for duvakitug to help treat and meaningfully improve the quality of life of people living with IBD," Hughes said.
The companies are working together on the next phase of development.
Teva and Sanofi said in November 2023 that they had closed a collaboration deal to co-develop and co-commercialize duvakitug. The companies will equally share the global development costs and net profits and losses in major markets, while other markets are subject to a royalty arrangement.
Sanofi agreed to lead the development of the Phase 3 program. Teva is leading commercialization of the product in Europe, Israel and specified other countries, while Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 17, 2024 08:30 ET (13:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。